



Atty. Dkt. No. 053466-0391  
JMC/je

UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Kiichiro YANO et al.  
Title: ANTI-AGING PREPARATION  
Appl. No.: 10/518,915  
Filing Date: 12/23/2004  
Examiner: Unassigned  
Art Unit: 1617

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

**RELEVANCE OF EACH DOCUMENT**

Some documents listed on the attached Form PTO/SB/08 were cited as being relevant during the prosecution of the corresponding International application. A copy of the International Search Report is attached setting forth the portion of each document considered relevant by the examiner. English language abstracts have been provided herewith.

Document A8 discloses an anti-aging agents which promote production of collagen and inhibits elastase activity.

Document A12 discloses certain plant extracts as promoters for production of hyaluronic acid which are effective in preventing the aging of human skin.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date July 5, 2005


FOLEY & LARDNER LLP  
Customer Number: 22428  
Telephone: (202) 672-5569  
Facsimile: (202) 672-5399

By Matthew E. Mulkeen

*for* Stephen B. Maebius *Matthew E. Mulkeen*  
Attorney for Applicant Reg. No. 44,250  
Registration No. 35,264

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
Date Submitted: July 5, 2005					
(use as many sheets as necessary)					
Sheet	1	of	2	Attorney Docket Number	053466-0391



## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
A1	5,837,224			Voorhees et al.	11/17/1998	

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
A2	JP	61-161208			Nisshin Oil Mills, Ltd.	07/21/1986		Abs
A3	JP	1-117815			Pola Chem Ind Inc.	05/10/1989		Abs
A4	JP	6-24937			Narisu Keshohin KK	02/01/1994		Abs
A5	JP	9-221410			Noevir Co. Ltd.	08/26/1997		Abs
A6	JP	10-330222			Pola Chem Ind Inc.	12/15/1998		Abs
A7	JP	11-12122			Pola Chem Ind Inc.	01/19/1999		Abs
A8	JP	11-335235			Shiseido Co. Ltd.	12/07/1999		Abs
A9	JP	2001-31521			Ichimaru Pharcos Co. Ltd.	02/06/2001		Abs
A10	JP	2001-115197			Take KK	04/24/2001		Abs
A11	JP	2001-139484			Lion Corp.	05/22/2001		Abs
A12	JP	2001-163794			Shiseido Co Ltd.	06/19/2001		Abs
A13	JP	2001-181169			Kao Corp.	07/03/2001		Abs
A14	JP	2001-226218			Ichimaru Pharcos Co Ltd.	08/21/2001		Abs
A15	JP	2001-333731			Ichimaru Pharcos Co Ltd.	12/04/2001		Abs
A16	PCT	WO 02/34885	A1		National Institute of Agrobiological Sciences	03/22/2001		Abs

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
A17		ISHIJIMA, Saori et al., "To Keep Skin Young: Tales of a High-Molecular Component, Kobunshi, 1995, Vol. 44, No. 6, pgs. 362-364.	
A18		METORI, Koichi et al., "The Preventive Effect of Ginseng with Du-Zhong Leaf on Protein Metabolism in Aging", BIOL. PHARM. BULL., 1997, Vol. 20, No. 3, pgs. 237-242.	
A19		MOCHIZUKI, Mami et al., "Inhibitory Effect of Tumor Metastasis in Mice by Saponins, Ginsenoside-Rb2, 20(R)- and 20(S)-Ginsenoside-Rg3, of Red ginseng", BIOL. PHARM. BULL., 1995, Vol. 18, No. 9, pgs. 1197-1202.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/518,915
Date Submitted: July 5, 2005 (use as many sheets as necessary)				Filing Date	12/23/2004
				First Named Inventor	Kiichiro YANO
				Group Art Unit	1617
				Examiner Name	Unassigned
Sheet	2	of	2	Attorney Docket Number	053466-0391



NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	A20	MORISAKI, Nobuhiro, "Kekkan Shinsei to Yakujo Ninjin", <i>BIOMEDICINE &amp; THERAPEUTICS</i> , Vol. 28, No. 1, pgs. 94-95.			T <sup>6</sup>
	A21	SATO, Katsuaki et al., "Inhibition of Tumor Angiogenesis and Metastasis by a Saponin of <i>Panax ginseng</i> , Ginsenoside-Rb2", <i>Biol. PHARM. BULL.</i> , 1994, Vol. 17, No. 5, pgs. 635-639.			
	A22	TAMURA, Hiroaki et al., "New Cosmetic Ingredients having Anti-aging", <i>FRAGRANCE JOURNAL</i> , 2000, Vol. 28, No. 12, pgs. 38-42, (pg. 40/3-2).			
	A23	TANAKA, Hiroshi et al., "Effect of panax ginseng on the production of glycoaminoglycans in cultured human skin fibroblast", <i>FRAGRANCE JOURNAL</i> , 1991, Vol. 28, No. 1, pgs. 90-92.			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.